» Articles » PMID: 30392076

The Role of CD47 in Pathogenesis and Treatment of Renal Ischemia Reperfusion Injury

Overview
Journal Pediatr Nephrol
Specialties Nephrology
Pediatrics
Date 2018 Nov 5
PMID 30392076
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Ischemia reperfusion (IR) injury is a process defined by the temporary loss of blood flow and tissue perfusion followed later by restoration of the same. Brief periods of IR can be tolerated with little permanent deficit, but sensitivity varies for different target cells and tissues. Ischemia reperfusion injuries have multiple causes including peripheral vascular disease and surgical interventions that disrupt soft tissue and organ perfusion as occurs in general and reconstructive surgery. Ischemia reperfusion injury is especially prominent in organ transplantation where substantial effort has been focused on protecting the transplanted organ from the consequences of IR. A number of factors mediate IR injury including the production of reactive oxygen species and inflammatory cell infiltration and activation. In the kidney, IR injury is a major cause of acute injury and secondary loss of renal function. Transplant-initiated renal IR is also a stimulus for innate and adaptive immune-mediated transplant dysfunction. The cell surface molecule CD47 negatively modulates cell and tissue responses to stress through limitation of specific homeostatic pathways and initiation of cell death pathways. Herein, a summary of the maladaptive activities of renal CD47 will be considered as well as the possible therapeutic benefit of interfering with CD47 to limit renal IR.

Citing Articles

Deciphering the role of CD47 in cancer immunotherapy.

Liu Y, Weng L, Wang Y, Zhang J, Wu Q, Zhao P J Adv Res. 2024; 63:129-158.

PMID: 39167629 PMC: 11380025. DOI: 10.1016/j.jare.2023.10.009.


Remote liver ischemic preconditioning protects against renal ischemia/reperfusion injury via phosphorylation of extracellular signal-regulated kinases 1 and 2 in mice.

Wang Q, Xiao J, Wei S, Yang X, Li J, Zuo Y PLoS One. 2024; 19(8):e0308977.

PMID: 39159207 PMC: 11332924. DOI: 10.1371/journal.pone.0308977.


Asiaticoside ameliorates renal ischemia/reperfusion injury by promoting CD4CD25FOXP3 treg cell differentiation.

Tang S, Xie X, Wang M, Wei W Heliyon. 2023; 9(7):e17390.

PMID: 37539103 PMC: 10395025. DOI: 10.1016/j.heliyon.2023.e17390.


How to Best Protect Kidneys for Transplantation-Mechanistic Target.

Akalay S, Hosgood S J Clin Med. 2023; 12(5).

PMID: 36902572 PMC: 10003664. DOI: 10.3390/jcm12051787.


Emerging phagocytosis checkpoints in cancer immunotherapy.

Liu Y, Wang Y, Yang Y, Weng L, Wu Q, Zhang J Signal Transduct Target Ther. 2023; 8(1):104.

PMID: 36882399 PMC: 9990587. DOI: 10.1038/s41392-023-01365-z.


References
1.
Hugo C, Kang D, Johnson R . Sustained expression of thrombospondin-1 is associated with the development of glomerular and tubulointerstitial fibrosis in the remnant kidney model. Nephron. 2002; 90(4):460-70. DOI: 10.1159/000054735. View

2.
Nath K, Grande J, Croatt A, Frank E, Caplice N, Hebbel R . Transgenic sickle mice are markedly sensitive to renal ischemia-reperfusion injury. Am J Pathol. 2005; 166(4):963-72. PMC: 1602372. DOI: 10.1016/S0002-9440(10)62318-8. View

3.
Nishiyama Y, Tanaka T, Naitoh H, Mori C, Fukumoto M, Hiai H . Overexpression of integrin-associated protein (CD47) in rat kidney treated with a renal carcinogen, ferric nitrilotriacetate. Jpn J Cancer Res. 1997; 88(2):120-8. PMC: 5921365. DOI: 10.1111/j.1349-7006.1997.tb00356.x. View

4.
Isenberg J, Maxhimer J, Powers P, Tsokos M, Frazier W, Roberts D . Treatment of liver ischemia-reperfusion injury by limiting thrombospondin-1/CD47 signaling. Surgery. 2008; 144(5):752-61. PMC: 2635486. DOI: 10.1016/j.surg.2008.07.009. View

5.
Powell R, Dyess D, Collins J, ROBERTS W, Tacchi E, Swafford Jr A . Regional blood flow response to hypothermia in premature, newborn, and neonatal piglets. J Pediatr Surg. 1999; 34(1):193-8. DOI: 10.1016/s0022-3468(99)90255-5. View